- Home
- ICLR vs RPRX Comparison
ICLR vs RPRX Comparison
Compare ICLR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICLR | RPRX |
|---|---|---|
| Founded | 1990 | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 16.4B |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ICLR | RPRX |
|---|---|---|
| Price | $185.42 | $39.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $201.46 | $45.75 |
| AVG Volume (30 Days) | 944.0K | ★ 3.3M |
| Earning Date | 02-18-2026 | 02-10-2026 |
| Dividend Yield | N/A | ★ 2.38% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.47 | 1.75 |
| Revenue | ★ $8,102,602,000.00 | $2,349,844,000.00 |
| Revenue This Year | N/A | $37.66 |
| Revenue Next Year | $0.39 | $2.34 |
| P/E Ratio | $24.43 | ★ $22.58 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $125.10 | $29.66 |
| 52 Week High | $211.00 | $41.70 |
Technical Indicators
Market Signals| Indicator | ICLR | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 49.50 |
| Support Level | $179.54 | $39.87 |
| Resistance Level | $185.99 | $40.58 |
| Average True Range (ATR) | 6.84 | 0.78 |
| MACD | -1.03 | -0.03 |
| Stochastic Oscillator | 41.24 | 34.46 |
Price Performance
Historical ComparisonAbout ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.